Cost Impact of Switching Histamine 2 -Receptor Antagonists to Nonprescription Status

Abstract

Spanish

French

BACKGROUND:

There is a recent trend to switching medications from prescription to nonprescription status. Often, such switches are accompanied by dramatic changes in utilization due to increased availability or decreased insurance coverage. The histamine₂-receptor antagonists (H₂RAs) underwent such status change in the UK in 1994, the US in 1995, and Canada in 1996.

OBJECTIVE:

To examine the impact of the status change for H₂RAs on the market for gastrointestinal (GI) agents in the US, UK, and Canada.

METHODS:

IMS market sales data from 1992 to 1997 were procured. All costs were converted to 1997 US dollars using the consumer price index. Per capita sales figures were determined using population data from the US Census Bureau's International Database.

RESULTS:

Overall spending on GI remedies increased in all 3 markets between 1992 and 1997; however, the contribution of prescription sales and number of prescriptions varied across the 3 countries. An increased market share for nonprescription H₂RAs occurred in the US, correlating with a decline in prescription numbers for GI remedies. The opposing trend occurred in the UK, where market share of nonprescription H₂RAs was minimal and use of prescription H₂RAs increased. Prescription and nonprescription H₂RA sales could not be differentiated for Canada.

CONCLUSIONS:

The impact of the H₂RA status change varied across countries. Differences in utilization may be attributed to many factors such as differing healthcare systems, patient convenience, and physician prescribing practices. Further research is required to identify the reasons for differences in utilization and to quantify the potential clinical impact.

Keywords

drug utilization OTC switch pharmacoepidemiology

Get full access to this article

View all access options for this article.

References

Kalish

Bohn

Avorn

. Policy analysis of the conversion of histamine₂ antagonists to over-the-counter use. Med Care 1997;35: 32–48.

Andersson

Hatziandreu

. The costs and benefits of switching a drug from prescription-only to over-the-counter status: A review of methodological issues and current evidence. Pharmacoeconomics 1992;2: 388–96.

Erwin

Britten

Jones

. General practitioners' views on the over-the-counter availability of H₂-antagonists. Br J Gen Pract 1997;47: 99–102.

Marsh

. Nonprescription H₂ receptor antagonists. J Am Pharm Assoc 1997;NS37:552–5.

Foy

. OTC H₂ antagonists. Can Pharm J 1996;129: 49–51.

Covington

, ed. Nonprescription drug therapy: guiding patient self-care. St. Louis, MO: Facts and Comparisons, 1999: 342–3.

Compendium of nonprescription products. Ottawa: Canadian Pharmaceutical Association, 1999:535, 536, 601–3.

McCormack

Brown

, eds. Drug therapy decision making guide. Philadelphia: WB Saunders, 1996: 52–5.

Holbrook

, Chair for Ontario GI Therapy Review Panel. Ontario guidelines for peptic ulcer disease and gastroesophageal reflux. 1st ed. Toronto: Queen's Printer of Ontario, 2000.

10.

Johnson and Johnson, Merck and SmithKline Beecham told to change H(2) adverts. Scrip 1995;2073(Suppl):6.

11.

Oster

Huse

Delea

Colditz

Richter

. The risks and benefits of an Rx-to-OTC switch. Med Care 1990;28: 834–52.

12.

Axid recommended for over-the-counter (OTC) status. Scrip 1995;2073 (Suppl):7.

13.

Hunt

. Habit, prejudice, power and politics: Issues in the conversion of H₂-receptor antagonists to over-the-counter. CMAJ 1996;154: 49–53.

14.

Felix

. H₂ antagonists take bite out of antacids. Pharm Post 1998;6(3):22.

15.

IMS Health — About IMS in Canada [cited 2001 November 19]. Available from: URL: http://www.imshealthcanada.com/htmen/2_0.htm.

16.

Academic reference manual. Mississauga, Ontario: IMS Health, 2001.

17.

International financial statistics. Washington, DC: International Monetary Fund, 1998(May);LI (5):156, 720, 728.

18.

US Census Bureau, international database. [cited 2000 May 15]. Available from: URL: http://www.census.gov/ipc/www/idbsum.html.

19.

World Health Organization. Anatomical therapeutic chemical (ATC) classification index including defined daily doses (DDDs) for plain substances. Olso: WHO Collaborating Centre for Drug Statistics Methodology, January 1995.

20.

US Census Bureau, current population survey, March 2000 and 2001. [cited 2001 December 25]. Available from: URL: http://www.census.gov/hhes/hlthins/hlthin00/dtable1.html.